Rhythm Pharmaceuticals (DE:1RV)
NASDAQ:1RV
1RV Stock Chart & Stats
€72.00
€1.00(1.77%)
At close: 4:00 PM EST
€72.00
€1.00(1.77%)
Day’s Range― - ―
52-Week Range€52.00 - €99.00
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€4.98B
Enterprise Value€6.22B
Total Cash (Recent Filing)€340.63M
Total Debt (Recent Filing)€227.02M
Price to Earnings (P/E)―
Beta0.10
Next Earnings
Aug 04, 2026EPS Estimate
-0.7Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.13
Shares Outstanding68,593,575
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio1.25
Price to Book (P/B)50.02
Price to Sales (P/S)36.66
P/FCF Ratio-59.64
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€117.81Price Target Upside63.63% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering14
EPS Forecast (FY)-2.68
Revenue Forecast (FY)€253.44M
Bulls Say, Bears Say
Bulls Say
Strong Revenue Scale And High Gross MarginsRhythm has moved from early commercialization to material top-line scale with TTM revenues ~ $217M and sustained gross margins near 90%. Those unit-economics support long-term profitability potential as patient identification and chronic dosing create recurring revenue per treated patient.
Regulatory Approvals Expanding Addressable MarketRecent U.S. approval for acquired hypothalamic obesity, an EMA positive opinion and a Japan filing materially broaden IMCIVREE's market footprint. Multi-region regulatory momentum creates a durable expansion of the treatable population and strengthens Rhythm's leadership in precision rare-obesity therapy.
Solid Near-term Liquidity And RunwayApproximately $341M of cash and short-term investments and a stated ≥24-month runway provide the company time to scale commercial launches, invest in CMC/clinical supply and advance pipeline programs without immediate refinancing, reducing near-term capital risk while execution continues.
Bears Say
Persistent Negative Operating And Free Cash FlowRhythm continues to convert losses into real cash outflows with TTM operating cash flow and free cash flow around -$120M. Ongoing negative cash generation forces reliance on existing cash or external financing to fund growth and clinical programs, constraining long-term financial flexibility.
Rising Leverage And Shrinking EquityDebt has grown while equity has fallen, producing elevated leverage (~1.85x). Higher debt and reduced equity limit strategic optionality, increase refinancing and interest-rate vulnerability, and reduce resilience to commercial variability or clinical setbacks over the medium term.
Surging Operating Expenses Driven By Launch InvestmentsRapid increases in SG&A and planned higher non-GAAP operating spending to support HO launches and CMC activities compress operating leverage. Until sustained conversion of launch activity to repeat prescriptions occurs, elevated spend may prolong unprofitability despite attractive gross margins.
Rhythm Pharmaceuticals News
1RV FAQ
What was Rhythm Pharmaceuticals’s price range in the past 12 months?
Rhythm Pharmaceuticals lowest stock price was €52.00 and its highest was €99.00 in the past 12 months.
What is Rhythm Pharmaceuticals’s market cap?
Rhythm Pharmaceuticals’s market cap is €4.98B.
When is Rhythm Pharmaceuticals’s upcoming earnings report date?
Rhythm Pharmaceuticals’s upcoming earnings report date is Aug 04, 2026 which is in 61 days.
How were Rhythm Pharmaceuticals’s earnings last quarter?
Rhythm Pharmaceuticals released its earnings results on May 05, 2026. The company reported -€0.712 earnings per share for the quarter, missing the consensus estimate of -€0.705 by -€0.007.
Is Rhythm Pharmaceuticals overvalued?
According to Wall Street analysts Rhythm Pharmaceuticals’s price is currently Undervalued.
Does Rhythm Pharmaceuticals pay dividends?
Rhythm Pharmaceuticals does not currently pay dividends.
What is Rhythm Pharmaceuticals’s EPS estimate?
Rhythm Pharmaceuticals’s EPS estimate is -0.7.
How many shares outstanding does Rhythm Pharmaceuticals have?
Rhythm Pharmaceuticals has 68,593,575 shares outstanding.
What happened to Rhythm Pharmaceuticals’s price movement after its last earnings report?
Rhythm Pharmaceuticals reported an EPS of -€0.712 in its last earnings report, missing expectations of -€0.705. Following the earnings report the stock price went up 8.209%.
Which hedge fund is a major shareholder of Rhythm Pharmaceuticals?
Currently, no hedge funds are holding shares in DE:1RV
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Rhythm Pharmaceuticals Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€117.81 (63.63% Upside)
€117.81 (63.63% Upside)
Blogger Sentiment
Bullish
DE:1RV Sentiment 70%
Sector Average ―
Sector Average ―
Insider Transactions
Sold Shares
Worth €801.7K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
28.99%
12-Months-Change
Fundamentals
Return on Equity
-203.25%
Trailing 12-Months
Asset Growth
14.39%
Trailing 12-Months
Company Description
Rhythm Pharmaceuticals
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity. The company's lead product candidate is IMCIVREE, a potent melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is also developing setmelanotide, which is in Phase II clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, Smith-Magenis syndrome obesity, POMC epigenetic disorders, and other MC4R disorders. Rhythm Pharmaceuticals, Inc. has a collaborative research agreement with the Clinical Registry Investigating Bardet-Biedl Syndrome. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
1RV Company Deck
1RV Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented a largely positive commercial and regulatory picture: sequential revenue growth (5%), strong international acceleration (27% QoQ outside U.S.), an encouraging early HO launch (150+ start forms, broad prescriber base), EU marketing authorization and a progressing Japan filing, supported by a solid cash runway (~$341M). Offsetting these positives are meaningful increases in operating expenses (notably SG&A up ~62.7% YoY), ongoing GAAP losses (Q1 EPS -$0.83) and near-term variability and uncertainty tied to payer policy timing, inventory effects and the pace of clinical-to-commercial conversions. Overall, the operational momentum and regulatory wins outweigh the financial and execution risks highlighted for the near term.View all DE:1RV earnings summaries1RV Stock 12 Month Forecast
Average Price Target
€117.81
▲(63.63% Upside)
Technical Analysis
Cytokinetics
―
TG Therapeutics
―
Legend Biotech
―
Atrium Therapeutics, Inc.
―
Abivax SA Sponsored ADR
―
Options Prices
Currently, No data available
---